NCT05327699View on ClinicalTrials.gov

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Major Depressive Disorder
Interventions
DRUG

Ketamine

A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.

OTHER

Placebo

A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.

Trial Locations (1)

30322

RECRUITING

Emory University, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER